Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates /631/326/596 /692/699/255/1901 /82/58 /38/91 /82/80 article 2018
2018 Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques 2018
2018 Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV 2018
2018 ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch’s Membrane and Causes Its Structural Remodeling 2018
2018 The apolipoprotein e mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophages 2018
2016 Apolipoprotein mimetic peptides as modulators of lipoprotein function 2016
2015 Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaques 2015
2015 Rectal application of a highly osmolar personal lubricant in a macaque model induces acute cytotoxicity but does not increase risk of SHIV infection 2015
2014 Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A review 2014
2014 Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A 2014
2014 Evaluation of pigtail macaques as a model for the effects of copper intrauterine devices on HIV infection 2014
2014 Pharmacokinetic and safety analyses of tenofovir and tenofovir- emtricitabine vaginal tablets in pigtailed macaques 2014
2014 Preclinical evaluation of the immunomodulatory lymphocyte trafficking drug FTY720 for HIV prevention in the female genital mucosa of macaques 2014
2013 Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats 2013
2013 Recent progress in the development of apoA-I and apoE mimetic therapies 2013
2013 Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice 2013
2013 In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathology 2013
2013 Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse 2013
2012 Deletion of specific immune-modulatory genes from modified vaccinia virus ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques 2012
2012 Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice 2012
2012 Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides 2012
2011 Apolipoprotein E mimetics and cholesterol-lowering properties 2011
2011 Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activators 2011
2011 Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques 2011
2011 Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques 2011
2010 ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity 2010
2010 Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice 2010
2010 Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects 2010
2010 Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2 2010
2009 Selective removal of stratum corneum by microdermabrasion to increase skin permeability 2009
2009 Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters 2009
2009 Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression 2009
2009 Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease 2009
2009 Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies 2009
2009 Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.). 2009
2008 HDL therapy for cardiovascular diseases: The road to HDL mimetics 2008
2007 Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape 2007
2007 Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing 2007
2007 Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides 2007
2007 ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers 2007
2006 Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus 2006
2006 Atherosclerosis and vascular disease: Effects of peptide mimetics of apolilpoproteins 2006
2006 Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus Ankara enhances antiviral cellular and humoral immune responses 2006
2006 Potential clinical utility of high-density lipoprotein-mimetic peptides 2006
2006 Synthetic peptides: Managing lipid disorders 2006
2006 Oral amphipathic peptides as therapeutic agents 2006
2005 An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice 2005
2005 Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide 2005
2005 Apolipoprotein A-I mimetic peptides - ATVB in focus 2005
2005 D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice 2005
2005 Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits 2005
2005 Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts 2005
2004 Human apolipoprotein A-I and A-I mimetic peptides: Potential for atherosclerosis reversal 2004
2004 Prospects for an AIDS vaccine: Three big questions, no easy answers 2004
2004 Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity 2004
2004 Roles of Target Cells and Virus-Specific Cellular Immunity in Primary Simian Immunodeficiency Virus Infection 2004
2004 Blockade of T cell costimulation reveals interrelated actions of CD4 + and CD8+ T cells in control of SIV replication 2004
2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. 2004
2003 Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis 2003
2003 AIDS vaccine development: The long and winding road 2003
2003 Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice 2003
2003 Association of Aortic Atherosclerosis with Cerebral β-Amyloidosis and Learning Deficits in a Mouse Model of Alzheimer's Disease 2003
2002 Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide 2002
2002 Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICP0 transcripts in mouse ganglia latently infected with herpes simplex virus 2002
2002 Sustained-delivery of an apolipoproteinE-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels 2002
2002 Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol 2002
2001 Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide 2001
2001 Toward the design of peptide mimics of antiatherogenic apolipoproteins A-I and E 2001
2001 Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo 2001
2001 A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis 2001
2000 Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation 2000
2000 A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples 2000
2000 The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts 2000
1997 Quantification of HDL2 and HDL3 cholesterol by the vertical auto profile-II (VAP-II) methodology 1997
1997 A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1 1997
1997 The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans 1997
1996 Chromatographic methods for quantitation of apolipoprotein A-I 1996
1995 A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol 1995
1995 Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology 1995
1994 ApoB-100 has a pentapartite structure composed of three amphipathic α-helical domains alternating with two amphipathic β-strand domains: Detection by the computer program LOCATE 1994
1994 Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors 1994
1994 Gene transfer to sensory neurons using herpes virus vectors. 1994
1994 Quantification of cholesterol in all lipoprotein classes by the VAP-II method 1994
1994 The amphipathic α helix: A multifunctional structural motif in plasma apolipoproteins 1994
1993 Cholesterol-lowering diets: Dealing with long-term adherence problems 1993
1993 Demonstration of circularization of herpes simplex virus DNA following infection using pulsed field gel electrophoresis 1993
1993 Thyroid function and other clinical chemistry parameters in subjects eating iodine-enriched eggs 1993
1992 Plasma lipoproteins in hyperlipidemic subjects eating iodine-enriched eggs 1992
1992 Saturated fats, cholesterol, and dietary compliance. 1992
1992 Analysis for cholesterol in all lipoprotein classes by single vertical ultracentrifugation of fingerstick blood and controlled-dispersion flow analysis 1992
1992 Gene transfer into mammalian central nervous system using herpes virus vectors: Extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter 1992
1992 Saturated Fats, Cholesterol, and Dietary Compliance 1992
1992 Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats: Correlation with physical properties 1992
1988 Ascites fluid lipoproteins in experimental nephrotic syndrome 1988
1985 Lipoproteins of ascites fluid from nephrotic rats 1985
1984 Catabolism of very low density lipoproteins in experimental nephrosis 1984

Research Overview

  • Coronary vascular disease, including heart disease and stroke, is the leading cause of death in the developed world. Numerous studies have shown that high levels of low density lipoprotein (LDL) cholesterol are associated with increased risk for atherosclerotic heart disease, while high levels of high density lipoprotein (HDL) are associated with reduced risk. The major protein component of HDL, apolipoprotein (apo) A-I, is considered to be primarily responsible for the atheroprotective properties of HDL. Apo E associates with chylomicrons, very low density lipoproteins (VLDL), and HDL, and mediates the clearance of triglyceride-rich lipoproteins. Both apo A-I and E have anti-inflammatory properties that contribute to atheroprotective properties.

    Our group has pioneered the design of peptide mimetics of apolipoproteins that have similar structural motifs as apo A-I and apo E, and has used these mimetic peptides to study the physical properties of apo A-I and apo E. My laboratory has extended these studies into animal models with the intent to use peptide mimetics of apolipoproteins to determine what properties of apo A-I and apo E prevent atherosclerosis and inflammatory processes in vivo. We are now extending these studies into animal models of Alzheimer ’s disease and insulin resistance.
  • Full Name

  • David Garber